SEARCH

SEARCH BY CITATION

References

  • 1
    Holdaway, I.M., Bolland, M.J. & Gamble, G.D. (2008) A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. European Journal of Endocrinology, 159, 8995.
  • 2
    Nomikos, P., Buchfelder, M. & Fahlbusch, R. (2005) The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical ‘cure’. European Journal of Endocrinology, 152, 379387.
  • 3
    Melmed, S., Colao, A., Barkan, A. et al. (2009) Guidelines for acromegaly management: an update. Journal of Clinical Endocrinology and Metabolism, 94, 15091517.
  • 4
    Freda, P.U., Katznelson, L., van der Lely, A.J. et al. (2005) Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. Journal of Clinical Endocrinology and Metabolism, 90, 44654473.
  • 5
    Howlett, T.A., Willis, D., Walker, G. et al. (2013) Control of Growth Hormone and IGF1 in patients with acromegaly in the UK: responses to medical treatment with somatostatin analogues and dopamine agonists. Clinical Endocrinology, doi:10.1111/cen.12207.
  • 6
    Trainer, P.J., Drake, W.M., Katznelson, L. et al. (2000) Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. The New England Journal of Medicine, 342, 11711177.
  • 7
    van der Lely, A.J., Hutson, R.K., Trainer, P.J. et al. (2001) Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. The Lancet, 358, 17541759.
  • 8
    Buchfelder, M., Schlaffer, S., Droste, M. et al. (2009) The German ACROSTUDY: past and present. European Journal of Endocrinology, 161(Suppl 1), S3S10.
  • 9
    Trainer, P.J. (2009) ACROSTUDY: the first 5 years. European Journal of Endocrinology, 161(Suppl 1), S19S24.
  • 10
    Veldhuis, J.D., Bidlingmaier, M., Anderson, S.M. et al. (2001) Lowering total plasma insulin-like growth factor I concentrations by way of a novel, potent, and selective growth hormone (GH) receptor antagonist, pegvisomant (B2036-peg), augments the amplitude of GH secretory bursts and elevates basal/nonpulsatile GH release in healthy women and men. Journal of Clinical Endocrinology and Metabolism, 86, 33043310.
  • 11
    Thorner, M.O., Strasburger, C.J., Wu, Z. et al. (1999) Growth Hormone (GH) receptor blockade with a PEG-modified GH (B2036-PEG) lowers serum insulin-like growth factor-I but does not acutely stimulate serum gh. Journal of Clinical Endocrinology and Metabolism, 84, 20982103.
  • 12
    Ørskov, H., Frystyk, J., Nielsen, C. et al. (2007) Concomitant, specific determination of growth hormone and pegvisomant in human serum. Growth Hormone and IGF Research, 17, 431434.
  • 13
    Jørgensen, J.O.L., Feldt-Rasmussen, U., Frystyk, J. et al. (2005) Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist. Journal of Clinical Endocrinology and Metabolism, 90, 56275631.
  • 14
    Parkinson, C., Burman, P., Messig, M. et al. (2007) Gender, body weight, disease activity, and previous radiotherapy influence the response to pegvisomant. Journal of Clinical Endocrinology and Metabolism, 92, 190195.
  • 15
    Colao, A., Pivonello, R., Auriemma, R.S. et al. (2006) Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance. European Journal of Endocrinology, 154, 467477.
  • 16
    Drake, W.M., Parkinson, C., Akker, S.A. et al. (2001) Successful treatment of resistant acromegaly with a growth hormone receptor antagonist. European Journal of Endocrinology, 145, 451456.
  • 17
    Lindberg-Larsen, R., Møller, N., Schmitz, O. et al. (2007) The impact of pegvisomant treatment on substrate metabolism and insulin sensitivity in patients with acromegaly. Journal of Clinical Endocrinology and Metabolism, 92, 17241728.
  • 18
    Frystyk, J., Dinesen, B. & Ørskov, H. (1995) Non-competitive time-resolved immunofluorometric assays for determination of human insulin-like growth factor I and II. Growth Regulation, 5, 169176.
  • 19
    Manolopoulou, J., Alami, Y., Petersenn, S. et al. (2012) Automated 22-kD growth hormone-specific assay without interference from Pegvisomant. Clinical Chemistry, 58, 14461456.
  • 20
    Roemmler, J., Steffin, B., Gutt, B. et al. (2009) The effect of acute application of pegvisomant alone and in combination with octreotide on endogenous GH levels during a 6-h test in patients with acromegaly on constant pegvisomant treatment. Growth Hormone and IGF Research, 19, 245251.
  • 21
    Barkan, A.L., Burman, P., Clemmons, D.R. et al. (2005) Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant. Journal of Clinical Endocrinology and Metabolism, 90, 56845691.
  • 22
    Pivonello, R., Galderisi, M., Auriemma, R.S. et al. (2007) Treatment with growth hormone receptor antagonist in acromegaly: effect on cardiac structure and performance. Journal of Clinical Endocrinology and Metabolism, 92, 476482.
  • 23
    Herman-Bonert, V.S., Zib, K., Scarlett, J.A. et al. (2000) Growth hormone receptor antagonist therapy in acromegalic patients resistant to somatostatin analogs. Journal of Clinical Endocrinology and Metabolism, 85, 29582961.
  • 24
    Rose, D.R. & Clemmons, D.R. (2002) Growth hormone receptor antagonist improves insulin resistance in acromegaly. Growth Hormone and IGF Research, 12, 418424.
  • 25
    Jimenez, C., Burman, P., Abs, R. et al. (2008) Follow-up of pituitary tumor volume in patients with acromegaly treated with pegvisomant in clinical trials. European Journal of Endocrinology, 159, 517523.
  • 26
    Buchfelder, M., Weigel, D., Droste, M. et al. (2009) Pituitary tumor size in acromegaly during pegvisomant treatment: experience from MR re-evaluations of the German Pegvisomant Observational Study. European Journal of Endocrinology, 161, 2735.
  • 27
    Buhk, J.H., Jung, S., Psychogios, M.N. et al. (2010) Tumor volume of growth hormone-secreting pituitary adenomas during treatment with pegvisomant: a prospective multicenter study. Journal of Clinical Endocrinology and Metabolism, 95, 552558.
  • 28
    van der Lely, A.J., Biller, B.M., Brue, T. et al. (2012) Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY. Journal of Clinical Endocrinology and Metabolism, 97, 15891597.
  • 29
    Marazuela, M., Lucas, T., Alvarez-Escola, C. et al. (2009) Long-term treatment of acromegalic patients resistant to somatostatin analogues with the GH receptor antagonist pegvisomant: its efficacy in relation to gender and previous radiotherapy. European Journal of Endocrinology, 160, 535542.
  • 30
    Nielsen, R.H., Doessing, S., Goto, K. et al. (2011) GH receptor blocker administration and muscle-tendon collagen synthesis in humans. Growth Hormone and IGF Research, 21, 140145.
  • 31
    Andreassen, M., Frystyk, J., Faber, J. et al. (2012) GH activity and markers of inflammation: a crossover study in healthy volunteers treated with GH and a GH receptor antagonist. European Journal of Endocrinology, 166, 811819.
  • 32
    Higham, C.E., Atkinson, A.B., Aylwin, S. et al. (2012) Effective combination treatment with cabergoline and low-dose pegvisomant in active acromegaly: a prospective clinical trial. Journal of Clinical Endocrinology and Metabolism, 97, 11871193.
  • 33
    Yin, D., Vreeland, F., Schaaf, L.J. et al. (2007) Clinical pharmacodynamic effects of the growth hormone receptor antagonist pegvisomant: implications for cancer therapy. Clinical Cancer Research, 13, 10001009.
  • 34
    Higham, C.E., Thomas, J.D., Bidlingmaier, M. et al. (2009) Successful use of weekly pegvisomant administration in patients with acromegaly. European Journal of Endocrinology, 161, 2125.
  • 35
    Muto, C., Chiba, K. & Suwa, T. (2011) Population pharmacokinetic and pharmacodynamic modeling of pegvisomant in Asian and Western acromegaly patients. Journal of Clinical Pharmacology, 51, 16281643.